Bayer's new business unit teams up with Mahana Therapeutics to commercialize digital treatments
Bayer is teaming up with Mahana Therapeutics in a “multi-million-dollar” distribution and marketing partnership to commercialize digital therapeutics, Mahana announced today.
Details in the statement from Mahana are sparse, and both companies declined to reveal more details about the dollar amount of the partnership.
Mahana CEO Simon Levy said in a statement the deal is “among the first major investments ever made by a global life sciences company into the emerging marketplace for digital therapeutics” and that the partnership is with Bayer’s consumer health division.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.